Villanova Investment Management Co LLC Purchases 32,737 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Villanova Investment Management Co LLC boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 167.1% in the second quarter, HoldingsChannel reports. The firm owned 52,324 shares of the specialty pharmaceutical company’s stock after buying an additional 32,737 shares during the quarter. Supernus Pharmaceuticals accounts for about 1.7% of Villanova Investment Management Co LLC’s holdings, making the stock its 24th largest holding. Villanova Investment Management Co LLC’s holdings in Supernus Pharmaceuticals were worth $1,649,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Armistice Capital LLC boosted its stake in shares of Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock worth $170,169,000 after buying an additional 360,000 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $4,393,000. Millennium Management LLC lifted its holdings in Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares during the period. Jane Street Group LLC purchased a new position in Supernus Pharmaceuticals in the first quarter worth $3,641,000. Finally, Public Sector Pension Investment Board boosted its position in Supernus Pharmaceuticals by 59.7% in the first quarter. Public Sector Pension Investment Board now owns 219,731 shares of the specialty pharmaceutical company’s stock worth $7,196,000 after purchasing an additional 82,167 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 1st. Finally, Bank of America assumed coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $63.25.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 5,000 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total value of $229,350.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at $710,801.52. This trade represents a 24.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $50.57, for a total value of $3,029,143.00. Following the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. The trade was a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 121,235 shares of company stock worth $5,923,797 in the last three months. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Trading Up 1.3%

Shares of SUPN stock opened at $45.68 on Monday. The firm’s 50 day moving average is $48.37 and its 200 day moving average is $41.41. The stock has a market capitalization of $2.62 billion, a P/E ratio of -134.35, a PEG ratio of 0.56 and a beta of 0.72. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The business had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 earnings per share. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.